What Dexak SL Treats: Main Uses and Benefits

Dexak SL is an analgesic and anti-inflammatory medication commonly used for the short-term symptomatic relief of acute physical discomfort. It is generally applied across domains where symptoms associated with acute or episodic changes arise suddenly, relevant when supportive symptom management is appropriate. It is used for managing pain and physical discomfort of mild to moderate intensity.

The medication helps address symptom clusters that include symptoms related to inflammatory or irritative states, and it is relevant for easing certain distressing symptoms in conditions characterized by periods of heightened discomfort. These commonly managed conditions include acute musculoskeletal pain, symptomatic relief for painful menstruation (dysmenorrhea), and acute dental pain.

Quick Fact: Relief for Pain and Inflammation

Dexak SL is applied across clinical settings that involve acute or disruptive symptom patterns, such as pain following minor procedures or discomfort from acute sprains and strains. This symptomatic support supports general well-being during symptomatic phases.

Dexak SL (dexketoprofen) is authorized for use in adults who do not have specific exclusionary medical conditions or physiological states. This drug is contraindicated (must not be used) in several specific populations, according to official regulatory documents.

Mandatory Exclusions (Contraindications):

• Hypersensitivity: Patients allergic to dexketoprofen, other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or excipients, or those with a history of NSAID-induced asthma, rhinitis, or hives.
• Severe Organ Dysfunction: Individuals with severe heart failure, or moderate to severe kidney or liver failure.
• Bleeding/GI Risk: Patients with active gastrointestinal ulceration or bleeding, a history of related complications from previous NSAID use, or a coagulation disorder.
• Age and Physiological State: Children and adolescents under 18 years of age (use not established), women in the third trimester of pregnancy, and breastfeeding women.

Conditional Use (Requires Caution):

Use requires special consideration and medical consultation for elderly patients, those with mild organ impairment, pre-existing cardiovascular risk factors (e.g., hypertension), or a history of inflammatory bowel disease.

Interactions with other medicines and products

Regulatory documents establish specific interaction patterns for Dexketoprofen (Dexak SL), primarily based on pharmacodynamic risk and exposure modification.

Official Interaction Restrictions

Co-administration is contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose salicylates (e.g., Acetylsalicylic acid ge 3 g/day), and high-dose Methotrexate (ge 15 mg/week). These restrictions address the documented, unacceptable additive risk of adverse effects.

Clinically Significant Interactions

Dexketoprofen has documented pharmacodynamic interactions that increase the risk of bleeding and ulceration when combined with Anticoagulants (such as Warfarin), Heparins, Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). A heightened risk of renal impairment (nephrotoxicity) is also documented with Diuretics, ACE Inhibitors, and Angiotensin II Receptor Antagonists.

Pharmacokinetic interactions lead to officially documented increased plasma concentrations of certain co-administered drugs. This includes Lithium and low-dose Methotrexate (<15 mg/week). Additionally, the co-administration of Probenecid is officially noted to increase the systemic exposure of Dexketoprofen itself.

Timing and Population Considerations

Administration timing rules exist for the oral solution form: for rapid relief of acute pain, official labeling requires administration at least 15 minutes before meals due to food slowing the rate of absorption. Furthermore, the official profile notes that the risk of serious interaction outcomes, such as gastrointestinal bleeding, is higher in elderly patients.

How Dexak SL Works: Mechanism of Action

Enzyme Inhibition and Prostaglandin Synthesis

Dexak SL (dexketoprofen trometamol) works primarily by inhibiting the Cyclooxygenase (COX) enzyme system . This action modifies a critical molecular step, inhibiting the conversion of arachidonic acid into eicosanoid mediators, including prostaglandins. This suppression of lipid mediators represents the primary mechanistic pathway.

---

Modulation of Local Signaling Cascades

Limiting prostaglandin production engages mechanisms that modulate signaling cascades within the periphery. The modification of this molecular step influences localized vascular and thermal signaling processes. This mechanism helps regulate the pathway activity that shapes systemic physiological outcomes.

---

Stereoselective Action

The drug is formulated as the S-(+)-enantiomer (dexketoprofen), which is the single stereoisomer responsible for the primary enzyme inhibitory activity. This targeted stereoselective approach results in a higher concentration of the active S-enantiomer at the target site, facilitating modulation of enzyme activity and limiting the concentration of eicosanoid mediators.

Official Administration Guidelines for Dexak SL

The usage of Dexak SL is characterized by specific instructions concerning route, dosage, and duration. This medicine is designated for short-term use only and is limited to the symptomatic period.

Administration Scope	Official Instruction
Route and Preparation	The contents of the single-dose sachet must be fully dissolved in a glass of water, stirred, and immediately ingested. The route is oral.
Standard Dosing	The typical recommended dose is 12.5 mg every 4 to 6 hours, or 25 mg every 8 hours. The total daily intake is not to exceed 75 mg.
Timing	To achieve the fastest possible effect, administration is required to occur at least 15 to 30 minutes before meals (on an empty stomach).
Population Adjustment	Therapy for older adults should be initiated at a reduced total daily dose of 50 mg. The same initial reduction is also required for patients with mild renal or hepatic impairment.
Procedural Principle	The general procedural rule is to administer the lowest effective dose for the shortest duration necessary; if a dose is missed, patients should not take a double dose.

Use Protocol Summary

The protocol establishes a standardized oral administration for acute pain relief, requiring preparation as a liquid solution taken preemptively before food. This framework establishes limits on maximum dosage and frequency while requiring initial dose reduction for specific populations, defining the boundaries of the medicine’s use. The medicine is not recommended for pediatric use as efficacy and safety have not been established.

Primary Efficacy Studies

Research has consistently investigated the effects of Dexketoprofen trometamol in adults with acute pain, particularly in instances of musculoskeletal injuries, dental pain, and dysmenorrhea. The primary studies, which included randomized, double-blind, placebo-controlled trials, reported symptom scores that were lower over the observation periods compared to placebo. The trials typically evaluated short-term treatment courses.

• The primary endpoint in efficacy research frequently involved measuring changes in pain scores using standardized scales.
• The most frequent adverse events noted in the clinical trials were mild gastrointestinal discomfort and headache.

---

Focus of Research

Research has focused on the compound's profile as the active, dextrorotatory enantiomer of ketoprofen. Findings from various analyses were mixed regarding the speed of initial effect; some data included information on initial changes in symptom scores, while other analyses found no statistically significant differences in the earliest measured time points.

---

Combination and Long-Term Research

Studies have also explored whether combination therapy (e.g., with specific analgesics like tramadol) results in differences in symptom recurrence rates when compared to monotherapy. This research has included open-label, non-randomized designs over several months to gather comparative data.

• The study protocol utilized a specific administration schedule for the participants.
• The study designs often noted limitations, such as the absence of a placebo group for direct comparison in some combination trials.

Long-term use (up to two years) was also examined to evaluate whether it was associated with symptom changes. The treatment was evaluated for tolerability during these studies. Certain patient groups, such as those with pre-existing severe renal failure, were generally not included in the research population.

Key Studies & References

1. Summary of Product Characteristics (SmPC) for Dexketoprofen Trometamol (Relevant Regulatory Document for Safety/Exclusions)

Common questions about Dexak SL (FAQ)

Q: Is Dexak SL the same type of drug as ibuprofen or naproxen?

Dexak SL is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This places it in the same pharmacological class of medicine as both ibuprofen and naproxen. This classification means it shares common anti-inflammatory and pain-relieving properties with other NSAIDs.

Q: How quickly does Dexak SL usually start working?

Official pharmacokinetic data indicates that the medicine is absorbed rapidly due to its formulation. Following oral administration, the maximum concentration of the drug in the blood is typically reached in about 30 minutes, generally within a range of 15 to 60 minutes.

Q: How long does the effect of Dexak SL last?

Clinical studies show that the analgesic (pain-relieving) effect of the medicine generally persists for approximately 4 to 6 hours after a dose is taken. The dosing schedule outlined in official instructions is typically based on this duration.

Q: Is Dexak SL commonly used for headaches or migraines?

Official documents state that this medicine is indicated for the short-term symptomatic treatment of mild to moderate acute pain. The explicitly mentioned indications are musculoskeletal pain, dental pain, and dysmenorrhoea (menstrual cramps).

Q: Does consuming alcohol while using Dexak SL cause problems?

Official warnings state that alcohol intake may increase the risk of specific side effects, particularly gastrointestinal issues, including the potential for bleeding. Therefore, the combination is generally cautioned against in regulatory documents.

Q: Does Dexak SL have a reputation for causing drowsiness?

Drowsiness is listed in the official documents as an uncommon side effect. Other central nervous system effects, such as dizziness and headache, are also documented as uncommon occurrences that may be experienced by some users.

Q: What are the most common side effects people report with Dexak SL?

According to official regulatory information, the most common side effects reported are categorized as gastrointestinal disturbances. These frequently include nausea, vomiting, abdominal pain, and diarrhoea.

Q: What are the signs of a serious, but rare, side effect from Dexak SL?

Official warnings describe which signs of serious reactions warrant stopping the treatment and immediately seeking medical attention. These may include signs of gastrointestinal bleeding (such as blood in stool or vomit), severe allergic reactions (like swelling or breathing difficulty), or severe skin reactions.

Q: Is Dexak SL thought to be physically addictive?

This medicine is a Non-Steroidal Anti-Inflammatory Drug (NSAID), a class not typically associated with dependence. The official drug label does not classify this medicine as a controlled substance and does not include warnings about dependence, abuse, or addiction for this compound.

Q: Does the time of day matter when taking Dexak SL?

Official administration instructions focus on the medicine's timing relative to meals rather than the time of day. For the fastest possible onset of pain relief, regulatory guidance emphasizes that the medicine should be taken at least 15 minutes before a meal.

Q: What is the difference between Dexak SL and the non-steroidal anti-inflammatory drugs available without a prescription?

The main official difference is its marketing status, as regulatory authorities have designated Dexak SL as a Prescription-Only Medicine (POM). This means it is generally not available for purchase without authorization from a healthcare professional.

Q: Are there any known issues with Dexak SL and driving or operating machinery?

Official warnings state that the medicine may slightly affect the ability to drive or operate machinery. This is due to the potential for uncommon side effects such as dizziness, drowsiness, or visual disturbances.

Q: Does Dexak SL affect the ability to get pregnant?

Official documents indicate that this medicine belongs to the NSAID class of drugs, which may transiently impair female fertility. This effect is generally expected to be reversible once the use of the medicine is stopped.

Q: How long after stopping Dexak SL will it be completely out of my system?

Official pharmacokinetic data describes the drug's rapid elimination profile. The medicine has a short elimination half-life of approximately 1.65 hours, meaning the active substance is quickly cleared from the body by metabolic processes.

Q: What if I forget to take a dose of Dexak SL?

The official instruction is to not take a double dose to compensate for the missed one. Instead, the guidance is to take the next scheduled dose as planned.

Q: What is the general consensus on long-term use of Dexak SL?

The medicine is officially indicated for short-term use only, and treatment must be limited to the symptomatic period. This limitation is required due to regulatory warnings that prolonged use is associated with higher risks, especially cardiovascular and gastrointestinal events.

Q: Why is it recommended to check with a healthcare provider about Dexak SL and other pain relievers?

This is recommended because official documents list serious potential interactions with other medicines. This includes other pain relievers (NSAIDs), anticoagulants, and certain medicines used to manage cardiovascular health, requiring professional guidance.

Q: Does Dexak SL contain gluten or lactose?

Official product information contains a detailed list of all excipients, or inactive ingredients, in the formulation. Patients who have specific concerns about common allergens like gluten or lactose are directed to review the full excipient list in the official patient information leaflet for their specific product version.

The official regulatory documents outline specific conditions for the storage and disposal of Dexak SL (dexketoprofen trometamol granules for oral solution).

Storage Conditions and Stability

No special temperature requirements are necessary for storing this medicine. The product must be kept in the original carton and sachet to protect the contents from light and moisture. It is mandatory to keep the medicine out of the sight and reach of children. The product must not be used after the expiry date printed on the packaging. Once the sachet is opened and the granules are dissolved, the resulting oral solution is for immediate use and cannot be stored for later consumption.

Disposal Instructions

Unused or expired Dexak SL must not be discarded via household waste or wastewater. Disposal should adhere to local pharmaceutical waste regulations, which often involves returning the product to a pharmacist or designated collection point.